Intra-Cellular Therapies (NASDAQ:ITCI) Sets New 52-Week High at $33.79


Share on StockTwits

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $33.79 and last traded at $33.70, with a volume of 6675 shares changing hands. The stock had previously closed at $32.02.

A number of research firms recently commented on ITCI. Royal Bank of Canada decreased their price objective on Intra-Cellular Therapies from $43.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, November 2nd. Cantor Fitzgerald increased their price objective on Intra-Cellular Therapies from $53.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, December 29th. BTIG Research decreased their price target on Intra-Cellular Therapies from $80.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, November 2nd. They noted that the move was a valuation call. BidaskClub raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, December 23rd. Finally, ValuEngine raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Tuesday, December 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $42.89.

The stock has a 50 day moving average price of $28.64 and a 200 day moving average price of $25.02. The company has a market cap of $2.75 billion, a P/E ratio of -10.51 and a beta of 1.43.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Saturday, November 14th. The biopharmaceutical company reported ($0.79) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.21. Intra-Cellular Therapies had a negative return on equity of 48.27% and a negative net margin of 1,985.32%. The company had revenue of $7.37 million for the quarter, compared to the consensus estimate of $6.52 million. On average, equities research analysts forecast that Intra-Cellular Therapies, Inc. will post -3.27 EPS for the current year.

In related news, insider Suresh K. Durgam sold 4,367 shares of the firm’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $32.12, for a total transaction of $140,268.04. Following the completion of the transaction, the insider now owns 21,851 shares in the company, valued at approximately $701,854.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sharon Mates sold 41,896 shares of the firm’s stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $32.01, for a total value of $1,341,090.96. Following the transaction, the chief executive officer now owns 1,175,288 shares of the company’s stock, valued at approximately $37,620,968.88. The disclosure for this sale can be found here. Insiders sold a total of 320,147 shares of company stock valued at $9,272,230 in the last quarter. Corporate insiders own 18.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. bought a new position in shares of Intra-Cellular Therapies during the third quarter worth approximately $41,000. Liberty One Investment Management LLC purchased a new stake in Intra-Cellular Therapies in the third quarter worth about $44,000. Point72 Hong Kong Ltd purchased a new stake in Intra-Cellular Therapies in the third quarter worth about $59,000. Parallel Advisors LLC bought a new stake in shares of Intra-Cellular Therapies during the third quarter valued at approximately $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Intra-Cellular Therapies by 19.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,555 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 1,245 shares during the period. Institutional investors and hedge funds own 61.09% of the company’s stock.

Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Story: What is Call Option Volume?

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.